Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 18/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812599 | 0.89 | ADAMTS5 (1.00) | ADAMTS5POLBKDM4EALOX12 | |
| SCHEMBL1814287 | 0.88 | ADAMTS5 (0.79) | ADAMTS5ADAMTS4TP53POLB | |
| SCHEMBL27757701 | 0.88 | ADAMTS5 (0.79) | ADAMTS5ADAMTS4TP53POLB | |
| SCHEMBL1813923 | 0.88 | ADAMTS5 (1.00) | ADAMTS5KDM4EALOX12 | |
| SCHEMBL1810280 | 0.87 | ADAMTS5 (0.77) | ADAMTS5ADAMTS4TP53POLB | |
| SCHEMBL1815144 | 0.86 | ADAMTS5 (0.76) | ADAMTS5ADAMTS4TP53POLB | |
| SCHEMBL1812011 | 0.84 | ADAMTS5 (0.80) | ADAMTS5ADAMTS4TP53POLB | |
| SCHEMBL1816099 | 0.84 | ADAMTS5 (1.00) | ADAMTS5ADAMTS4KDM4EALOX12 | |
| SCHEMBL2153807 | 0.83 | ALOX12 (0.75) | ADAMTS5ADAMTS4TP53POLBKDM4E | |
| SCHEMBL24634764 | 0.82 | HSP90AA1 (0.75) | ADAMTS5ADAMTS4TP53POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | claimed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | claimed |
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | ADAMTS5 11/4885ADAMTS4 14/4885TP53 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.